

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A method for the intra-operative treat[[e]]ment of a tumor to inhibit dissemination of tumor cells, which comprises administering to the patient an antibody directed against a tumor-associated antigen during an intra-operative treatment whereby immunocomplexing of tumor cells within the scope of the surgical intervention inhibits dissemination of tumor cells, and wherein the administration of said antibody is carried out within 4 hours prior to surgery, during surgery or both, and wherein said immunocomplexing activates an antibody-dependent cellular cytotoxicity effector function and a complement dependent cytotoxicity effector function.
2. **(Previously Presented)** The method according to claim 1, wherein the antibody is directed against an epitope of a surface antigen of a tumor cell.
3. **(Currently Amended)** The method according to claim 1 or 2, wherein the tumor cells are from ~~is an~~ epithelial tumor-cell.
4. **(Currently Amended)** The method according to claim 1, wherein the antibody is directed against an epitope of an antigen selected from the group consisting of peptides, proteins, carbohydrates, and glycolipids.
5. **(Previously Presented)** The method according to claim 1, wherein the antibody is in an antibody mixture of various antibodies having a specificity for tumor-associated antigens.
6. **(Canceled)**
7. **(Currently Amended)** The method according to claim 1, wherein the antibody binds to the tumor-associated antigen with an affinity ~~corresponding to a dissociation constant below a Kd~~ value of 10^{-6} mol/l.

8. **(Currently Amended)** The method according to claim 1, wherein the source of said antibody is a mouse or a human. ~~derived from murine, chimeric, humanized and/or human sources.~~
9. **(Currently Amended)** The method according to claim 1, wherein the antibody is administered systemically ~~used with~~ in a single dose of at least 50 mg per patient.
10. **(Previously Presented)** The method according to claim 1, wherein the antibody is locally applied to the tumor tissue and/or to the wound area.
11. **(Canceled)**
12. **(Previously Presented)** The method according to claim 1, wherein the surgical intervention is carried out for a biopsy and/or for the removal of a solid tumor.
13. **(Currently Amended)** The method according to claim 1, wherein the surgical intervention is carried out for ~~[[a]]~~ the purpose of determining ~~ation regarding the malignancy of~~ a tumor.
14. **(Currently Amended)** The method according to claim 1, wherein ~~the immune complexes of the antibody and tumor tissues are is-determined on the immunocomplexed tumor tissue after~~ the immune complexes of the antibody and tumor tissues are determined on the immunocomplexed tumor tissue after the surgical intervention.
15. **(Currently Amended)** The method according to claim 1, wherein ~~the immune complexes of the antibody and~~ the immune complexes of the antibody ~~is-determined on tumor cells in blood or serum samples are determined.~~
16. **(Withdrawn)** A kit for the intra-operative treatment of tumor patients, comprising
 - a) a medicament based on an antibody directed against a tumor-associated antigen, and
 - b) a means for the diagnostic determination of malignant tumor cells which are immunocomplexed with the antibody.

17. **(Previously Presented)** The method according to claim 4, wherein the antigen is a member selected from the group consisting of EpCAM, NCAM, CEA, Lews Y, Sialyl-TN, Globo H, GD2, GD3 and GM2.
18. **(Previously Presented)** The method according to claim 7, wherein said Kd value is 10^{-7} mol/l.
19. **(Previously Presented)** The method according to claim 7, wherein said Kd value is 10^{-8} mol/l.
20. **(Currently Amended)** The method according to claim 89, wherein said single ~~doses~~ dose is at least 100 mg.
21. **(Currently Amended)** The method according to claim 89, wherein said single ~~doses~~ dose is at least 200 mg.
22. **(Currently Amended)** The method according to claim 89, wherein said single ~~doses~~ dose is at most 2 g. ~~mg.~~
23. **(Canceled)**
24. **(Canceled)**
25. **(Previously Presented)** The method according to claim 4, wherein said antibody is directed against an epitope of a carbohydrate tumor associated antigen.
26. **(Previously Presented)** The method according to claim 25, wherein said antigen is a member selected from the group consisting of Lewis Y, Glob H, Sialyl-TN, GD2 and GD3.
27. **(Previously Presented)** The method according to claim 26, wherein said antigen is Lewis Y antigen.

28. **(Canceled)**

29. **(Currently Amended)** A method for the intra-operative treatment of a tumor to inhibit dissemination of tumor cells, which comprises administering to the patient an antibody directed against the tumor-associated antigen Lewis Y during an intra-operative treatment whereby immunocomplexing of tumor cells within the scope of the surgical intervention inhibits dissemination of tumor cells, and wherein the administration of said antibody is carried out within 4 hours prior to surgery, during surgery or both, and wherein said immunocomplexing activates an antibody-dependent cellular cytotoxicity effector function and a complement dependent cytotoxicity effector function.

30. **(Previously Presented)** The method according to claim 29, wherein the antibody is administered during or immediately before the surgical intervention

31. **(Previously Presented)** The method according to claim 29, wherein the antibody is administered during the surgical intervention.

32. **(Currently Amended)** The method according to claim 29, wherein the tumor cells is-are from an epithelial tumor-cell.

33. **(Canceled)**

34. **(Currently Amended)** The method according to claim 29, wherein the antibody binds to the tumor-associated antigen with an affinity ~~corresponding to a dissociation constant below a~~ Kd value of 10^{-6} mol/l.

35. **(Currently Amended)** The method according to claim 29, ~~characterized in that the~~ wherein said antibody is a human or a mouse antibody derived from murine, chimeric, humanized and/or human sources.

36. **(Currently Amended)** The method according to claim 29, wherein the antibody is administered systemically ~~used within~~ a single dose of at least 50 mg per patient.

37. **(Previously Presented)** The method according to claim 29, wherein the antibody is locally applied to the tumor tissue and/or to the wound area.

38. **(Previously Presented)** The method according to claim 29, wherein the surgical intervention is carried out for a biopsy and/or for the removal of a solid tumor.

39. **(Previously Presented)** The method according to claim 29, wherein the surgical intervention is carried out for a determination regarding the malignancy of a tumor.

40. **(Currently Amended)** The method according to claim 29, wherein immunocomplexes of the antibody ~~and is determined on tumor cells in blood or serum samples~~ are determined.

41. **(Currently Amended)** The method according to claim 34 40, wherein said Kd value below ~~is~~ is 10^{-7} mol/l.

42. **(Currently Amended)** The method according to claim 34 -40, wherein said Kd value is 10^{-8} mol/l.

43. **(Currently Amended)** The method according to claim 36 -42, wherein said single dose is at most 2 mg.

44. **(Withdrawn)** The method according to claim 29, wherein the antibody is administered within 24 hours before the surgical intervention.

45. **(Withdrawn)** The method according to claim 29, wherein the antibody is administered within 4 hours before the surgical intervention.

46. **(New)** The method according to claim 1, wherein said antibody is a chimeric antibody or a humanized antibody.

47. **(New)** The method according to claim 29, wherein said antibody is a chimeric antibody or a humanized antibody.